In agreement with the obtained findings, Ji et al. [55] revealed that the neuroprotective impacts of selenium nanoformulations are primarily mediated by the activation of AChE in an Alzheimer’s disease model. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.